Menu
Close
Global
×

Company News

Home Company News News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
678
Previous article：ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2025-03-06
Approval by the NMPA for Clinical Trial of IMM01 (timdarpacept) Combined with IMM2510 (palverafusp α) and with or without Chemotherapy for Advanced Malignant Tumors
More
2025-01-13
ImmuneOnco IMM2510 Combined with Chemotherapy for First-Line NSCLC Treatment Completes Enrollment of First Patient in Phase Ib/II Clinical Trial
More
2024-11-13
The Phase II clinical trial of IMM27M for estrogen receptor positive (ER+) advanced breast cancer that failed after endocrine therapy or recurred and has enrolled the first patient
More

For more information

Please follow the official wechat public account